Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02302430 · ClinicalTrials.gov registry record · Phase 1
Intranasal Oxytocin and Enhancement of Team Cohesion
A Phase 1 study of Unit Cohesion, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 486
- Enrollment target
- 1
- Study location
NCT02302430 is a Phase 1 study of Unit Cohesion that has completed, run by University of California, San Francisco. The registered enrollment target is 486 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02302430, a Phase 1 study of Unit Cohesion, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 486 participants
- Enrollment target
- 1
- Study location
Study Summary
This study attempts to identify the psychological, behavioral, physiological, and hormonal predictors and mechanisms of an individual's ability to develop cohesion in a group working together as a team; and examine if administration of the prosocial neuropeptide oxytocin enhances the development of team cohesion. Through a deeper understanding of the underlying psychobiological predictors and mechanisms of team cohesion, the prospective identification of individuals whose unique characteristics promote or inhibit the development of group cohesion will become possible.
Conditions Studied
Interventions
- DRUG Oxytocin
- OTHER Placebo comparator
Study Locations (1)
California
- San Francisco VA Medical Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 486 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02302430
The ClinicalTrials.gov registry entry for NCT02302430 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 486 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unit Cohesion appearing as the primary indexed condition, and to 2 interventions - of which Oxytocin is the first listed.
NCT02302430 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02302430 about?
NCT02302430 is a clinical study titled "Intranasal Oxytocin and Enhancement of Team Cohesion". This study attempts to identify the psychological, behavioral, physiological, and hormonal predictors and mechanisms of an individual's ability to develop cohesion in a group working together as a team; and examine if administration of the prosocial neuropeptide oxytocin enhances the development of ...
What is the current status of trial NCT02302430?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 486 participants. The study started on 2015-10. Estimated completion is 2019-05-31.
What conditions does trial NCT02302430 study?
This clinical trial studies the following conditions: Unit Cohesion.
What interventions are being tested in trial NCT02302430?
The interventions under investigation include: Oxytocin (DRUG), Placebo comparator (OTHER).
Who is sponsoring clinical trial NCT02302430?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02302430 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.